FDA Warns of Risks Associated With Intraocular Use of Moxifloxacin
According to the Agency, 29 reports of TASS were identified following a search of the FDA Adverse Event Reporting System database through December 19, 2019.
Ophthalmic Disorders
EyeArt Autonomous AI System Cleared for Diabetic Retinopathy Screening
EyeArt is the first FDA-cleared AI technology for autonomous detection of more than mild diabetic retinopathy and vision-threatening diabetic retinopathy.
New Drug Product: Durysta
This slideshow shows drug information for Durysta. Click here for the complete Durysta monograph.
Glaucoma Patients Worry About Managing Disease During Pandemic
Delayed or canceled appointments during lockdown causing the greatest concern.
New Drug Product: Uplizna
This slideshow shows drug information for Uplizna. Click here for the complete Uplizna monograph.
Olopatadine 0.7% Eye Drops Approved for Sale Over-the-Counter
The FDA has approved Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride 0.7%; Alcon) ophthalmic solution, formerly prescribed as Pazeo®, for sale over-the-counter.
Upneeq Approved for Acquired Blepharoptosis
The FDA has approved Upneeq™ (oxymetazoline hydrochloride ophthalmic solution; Osmotica) for the treatment of acquired blepharoptosis in adults.
Beovu Labeling Updated With Additional Safety Information
The Food and Drug Administration (FDA) has approved updated labeling for Beovu® (brolucizumab; Novartis) to include additional safety information regarding the risk of retinal vasculitis and retinal vascular occlusion. Beovu received FDA approval in October 2019 for the treatment of wet age-related macular degeneration (wet AMD). The Warnings and Precautions section has been updated with…
Eysuvis Under Review for Dry Eye Disease
The FDA has accepted for review the New Drug Application for Eysuvis™ (loteprednol etabonate ophthalmic suspension; Kala Pharmaceuticals) 0.25% for the treatment of dry eye disease.
Varenicline Nasal Spray Improves Signs, Symptoms of Dry Eye Disease in Trial
Positive topline data were announced from the phase 3 ONSET-2 study of OC-01 (varenicline; Oyster Point Pharma) nasal spray for the treatment of the signs and symptoms of dry eye disease.
